Literature DB >> 9076202

Temporal corneal phacoemulsification combined with superior trabeculectomy. A retrospective case-control study.

H J Park1, M Weitzman, J Caprioli.   

Abstract

OBJECTIVE: To determine the results of temporal corneal phacoemulsification combined with separate-incision superior trabeculectomy plus low-dose 5-fluorouracil compared with trabeculectomy plus low-dose 5-fluorouracil.
DESIGN: Retrospective case-control study. PATIENTS: Forty consecutive case patients who underwent temporal corneal phacoemulsification combined with superior trabeculectomy plus low-dose 5-fluorouracil (case [combined surgery] group) and 40 control patients, matched for age race, preoperative intraocular pressure (IOP), number of preoperative antiglaucoma medications, and number of 5-fluorouracil injections, who underwent trabeculectomy alone plus low-dose 5-fluorouracil (control [trabeculectomy] group). MAIN OUTCOME MEASURES: Survival analyses for IOP control compared between the 2 groups.
METHODS: The medical records of 40 consecutive case patients were reviewed to determine the effect of their treatment on IOP, visual acuity, and requirement for glaucoma medications. In the control group, 40 eyes (1 eye per patient) were randomly selected for comparison with the case group. In both groups, the trabeculectomy was located superiorly and performed with the same technique and using a limbus-based conjunctival flap. In the case group, temporal corneal phacoemulsification immediately preceded trabeculectomy and used a 3.2-mm incision and a 1-piece silicone intraocular lens. All patients received 3 or 4 subconjunctival 5-fluorouracil injections of 5 mg each within the first 11 postoperative days. Patients were followed up for at least 1 year. Success of surgery was defined as an IOP of less than 22 mm Hg and a 20% or more reduction from the preoperative level on 2 consecutive follow-up visits, regardless of the use of antiglaucoma medications.
RESULTS: The mean (+/-SD) postoperative IOP was statistically higher in the case group than in the control group at each follow-up interval (P < .05). The mean (+/-SD) IOP reductions at 1 year were 6.8 +/- 5.5 mm Hg and 10.3 +/- 7.6 mm Hg (39.2% +/- 18.8%) in the case and control groups, respectively (P = .04). The reductions in the mean (+/-SD) number of antiglaucoma medications at 1 year were 1.6 +/- 0.9 and 2.0 +/- 1.0 in the case and control groups, respectively (P = .06). In the case group, the mean visual acuity beyond the first postoperative month was significantly better than at baseline (P < .001). Kaplan-Meier survival analysis showed that the cumulative success rates at 2 years were 62.1% and 85.8% in the case and control groups, respectively. The survival time to failure was significantly shorter (P = .04) in the case group by the log-rank test.
CONCLUSIONS: Combined surgery for cataract and glaucoma is associated with less long-term IOP reduction compared with trabeculectomy alone despite identical trabeculectomy techniques used in both groups. Nevertheless, combined surgery lowers IOP and reduces the long-term requirement for antiglaucoma medications. This technique is appropriate in selected patients with coexisting cataract and glaucoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9076202     DOI: 10.1001/archopht.1997.01100150320002

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  11 in total

1.  Anterior chamber flare after trabeculectomy and after phacoemulsification.

Authors:  D Siriwardena; A Kotecha; D Minassian; J K Dart; P T Khaw
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

2.  Long term effect on intraocular pressure of phacotrabeculectomy compared to trabeculectomy.

Authors:  J Lochhead; R J Casson; J F Salmon
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

3.  Success rates of 2-site phacoemulsification combined with fornix-based trabeculectomy using mitomycin C for primary angle-closure glaucoma and primary open-angle glaucoma in an Asian population.

Authors:  Victor Koh; David Chen; Cecilia Maria Aquino; Joel Aduan; Chelvin Sng; Loon Seng Chee; Paul Chew
Journal:  Jpn J Ophthalmol       Date:  2017-02-10       Impact factor: 2.447

4.  Temporal corneal phacoemulsification in filtered glaucoma patients.

Authors:  J Caprioli; H J Park; Y H Kwon; M Weitzman
Journal:  Trans Am Ophthalmol Soc       Date:  1997

5.  A prospective trial of phaco-trabeculotomy combined with deep sclerectomy versus phaco-trabeculectomy.

Authors:  Christoph Lüke; Thomas S Dietlein; Matthias Lüke; Walter Konen; Günter K Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-15       Impact factor: 3.117

6.  Otago Glaucoma Surgery Outcome Study: long term results of cataract extraction combined with Molteno implant insertion or trabeculectomy in primary glaucoma.

Authors:  A C B Molteno; K W Whittaker; T H Bevin; P Herbison
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

7.  Cataract surgery in eyes with filtered primary angle closure glaucoma.

Authors:  Sasan Moghimi; Golshan Latifi; Heydar Amini; Masood Mohammadi; Ghasem Fakhraie; Yadollah Eslami; Nariman Nassiri; Joseph Caprioli
Journal:  J Ophthalmic Vis Res       Date:  2013-01

8.  Surgical outcomes of uveitic glaucoma.

Authors:  Ester Carreño; Sonia Villarón; Alejandro Portero; José M Herreras; José A Maquet; Margarita Calonge
Journal:  J Ophthalmic Inflamm Infect       Date:  2010-11-18

Review 9.  Standalone XEN45 Gel Stent implantation versus combined XEN45-phacoemulsification in the treatment of open angle glaucoma-a systematic review and meta-analysis.

Authors:  Sheng Yang Lim; Bjorn Kaijun Betzler; Leonard Wei Leon Yip; Syril Dorairaj; Bryan Chin Hou Ang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-29       Impact factor: 3.535

10.  Visual and refractive outcome of one-site phacotrabeculectomy compared with temporal approach phacoemulsification.

Authors:  Daniela Vaideanu; Kaveri Mandal; Anthony Hildreth; Scott G Fraser; Peter S Phelan
Journal:  Clin Ophthalmol       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.